UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $379.88 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 0.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 751,900 shares of the company's stock after purchasing an additional 2,463 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.92% of IDEXX Laboratories worth $379,875,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of IDXX. Chicago Partners Investment Group LLC raised its holdings in shares of IDEXX Laboratories by 16.7% in the third quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock valued at $340,000 after buying an additional 96 shares during the last quarter. Manning & Napier Advisors LLC bought a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $20,418,000. Oppenheimer Asset Management Inc. grew its stake in shares of IDEXX Laboratories by 13.8% during the second quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company's stock valued at $5,825,000 after purchasing an additional 1,453 shares during the last quarter. National Pension Service increased its holdings in shares of IDEXX Laboratories by 7.3% in the third quarter. National Pension Service now owns 185,972 shares of the company's stock valued at $93,957,000 after purchasing an additional 12,647 shares in the last quarter. Finally, EFG Asset Management Americas Corp. raised its position in IDEXX Laboratories by 45.3% in the 2nd quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company's stock worth $6,201,000 after purchasing an additional 3,966 shares during the last quarter. Institutional investors own 87.84% of the company's stock.

Wall Street Analyst Weigh In

IDXX has been the subject of several research reports. Barclays lowered their target price on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a research report on Thursday, October 10th. JPMorgan Chase & Co. cut their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday. Finally, Piper Sandler restated a "neutral" rating and issued a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $552.38.

IDEXX Laboratories Trading Down 0.0 %

NASDAQ IDXX traded down $0.01 during trading on Friday, reaching $421.75. 338,607 shares of the stock traded hands, compared to its average volume of 505,750. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The firm has a market cap of $34.53 billion, a price-to-earnings ratio of 40.67, a price-to-earnings-growth ratio of 3.68 and a beta of 1.36. The stock's 50-day moving average price is $451.91 and its 200 day moving average price is $478.11.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating analysts' consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million during the quarter, compared to analysts' expectations of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm's quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.53 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

Insider Transactions at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now owns 905 shares of the company's stock, valued at $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.